This company has been marked as potentially delisted and may not be actively trading. Genesis Healthcare (GEN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipTrendsBuy This Stock GEN vs. SNPS, ADSK, TEAM, SNOW, RBLX, EA, TTWO, NET, VEEV, and XYZShould you be buying Genesis Healthcare stock or one of its competitors? The main competitors of Genesis Healthcare include Synopsys (SNPS), Autodesk (ADSK), Atlassian (TEAM), Snowflake (SNOW), Roblox (RBLX), Electronic Arts (EA), Take-Two Interactive Software (TTWO), Cloudflare (NET), Veeva Systems (VEEV), and Block (XYZ). These companies are all part of the "prepackaged software" industry. Genesis Healthcare vs. Synopsys Autodesk Atlassian Snowflake Roblox Electronic Arts Take-Two Interactive Software Cloudflare Veeva Systems Block Synopsys (NASDAQ:SNPS) and Genesis Healthcare (NYSE:GEN) are both large-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership. Which has more risk and volatility, SNPS or GEN? Synopsys has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Genesis Healthcare has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Is SNPS or GEN more profitable? Synopsys has a net margin of 36.12% compared to Genesis Healthcare's net margin of 17.83%. Genesis Healthcare's return on equity of 155.48% beat Synopsys' return on equity.Company Net Margins Return on Equity Return on Assets Synopsys36.12% 20.48% 13.51% Genesis Healthcare 17.83%155.48%9.12% Do institutionals and insiders believe in SNPS or GEN? 85.5% of Synopsys shares are held by institutional investors. Comparatively, 82.1% of Genesis Healthcare shares are held by institutional investors. 0.6% of Synopsys shares are held by company insiders. Comparatively, 3.3% of Genesis Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to SNPS or GEN? In the previous week, Synopsys had 30 more articles in the media than Genesis Healthcare. MarketBeat recorded 30 mentions for Synopsys and 0 mentions for Genesis Healthcare. Synopsys' average media sentiment score of 1.26 beat Genesis Healthcare's score of 0.00 indicating that Synopsys is being referred to more favorably in the media. Company Overall Sentiment Synopsys Positive Genesis Healthcare Neutral Which has better valuation & earnings, SNPS or GEN? Synopsys has higher revenue and earnings than Genesis Healthcare. Genesis Healthcare is trading at a lower price-to-earnings ratio than Synopsys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynopsys$6.07B11.70$2.26B$13.5233.98Genesis Healthcare$2.80B5.91$836M$0.9028.74 Do analysts recommend SNPS or GEN? Synopsys presently has a consensus target price of $613.43, indicating a potential upside of 33.54%. Genesis Healthcare has a consensus target price of $31.50, indicating a potential upside of 21.76%. Given Synopsys' stronger consensus rating and higher probable upside, analysts plainly believe Synopsys is more favorable than Genesis Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synopsys 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92Genesis Healthcare 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer SNPS or GEN? Synopsys received 367 more outperform votes than Genesis Healthcare when rated by MarketBeat users. Likewise, 72.59% of users gave Synopsys an outperform vote while only 65.43% of users gave Genesis Healthcare an outperform vote. CompanyUnderperformOutperformSynopsysOutperform Votes84272.59% Underperform Votes31827.41% Genesis HealthcareOutperform Votes47565.43% Underperform Votes25134.57% SummarySynopsys beats Genesis Healthcare on 16 of the 18 factors compared between the two stocks. Get Genesis Healthcare News Delivered to You Automatically Sign up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEN vs. The Competition Export to ExcelMetricGenesis HealthcarePrepackaged software IndustryBusiness SectorNYSE ExchangeMarket Cap$16.53B$24.73B$22.15B$18.96BDividend Yield3.05%1.94%2.58%4.01%P/E Ratio28.74114.4630.6832.87Price / Sales5.9118.20171.4928.03Price / Cash8.4286.0631.5117.52Price / Book-161.698.605.024.47Net Income$836M$438.40M$194.53M$1.02B Genesis Healthcare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GENGenesis Healthcare1.6414 of 5 stars$25.87+0.8%$31.50+21.8%+27.5%$16.53B$2.80B28.742,700SNPSSynopsys4.9142 of 5 stars$402.36-2.7%$618.31+53.7%-13.5%$62.21B$6.07B27.7119,000Analyst ForecastPositive NewsADSKAutodesk4.4629 of 5 stars$254.27-2.0%$321.59+26.5%+28.8%$54.16B$6.13B50.4512,600Positive NewsTEAMAtlassian4.7051 of 5 stars$192.84-4.9%$297.73+54.4%+32.5%$50.52B$4.79B-143.918,810Earnings ReportInsider TradeShort Interest ↑Positive NewsSNOWSnowflake4.4828 of 5 stars$136.76-4.7%$201.76+47.5%+2.8%$45.14B$3.63B-40.343,990Insider TradePositive NewsGap UpRBLXRoblox3.0509 of 5 stars$60.01+0.5%$64.00+6.6%+88.4%$37.71B$3.60B-41.392,130Earnings ReportOptions VolumeAnalyst RevisionPositive NewsEAElectronic Arts4.0006 of 5 stars$141.93-2.5%$154.65+9.0%+14.4%$36.99B$7.35B36.1112,900Upcoming EarningsAnalyst RevisionNews CoverageTTWOTake-Two Interactive Software3.7303 of 5 stars$205.16-3.6%$213.86+4.2%+63.4%$36.21B$5.45B-9.627,800Analyst RevisionPositive NewsNETCloudflare3.6428 of 5 stars$102.27-5.2%$134.84+31.8%+38.4%$35.29B$1.67B-464.863,220Upcoming EarningsInsider TradePositive NewsVEEVVeeva Systems3.6688 of 5 stars$210.09-2.7%$256.32+22.0%+17.8%$35.13B$2.75B51.875,480Positive NewsXYZBlock4.6854 of 5 stars$52.39-2.8%$90.14+72.1%-19.9%$32.45B$24.12B11.5112,985News Coverage Related Companies and Tools Related Companies SNPS Alternatives ADSK Alternatives TEAM Alternatives SNOW Alternatives RBLX Alternatives EA Alternatives TTWO Alternatives NET Alternatives VEEV Alternatives XYZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:GEN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genesis Healthcare, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genesis Healthcare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GEN Stock Free GEN Stock Alerts